Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05131646 · ClinicalTrials.gov registry record

Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study

A clinical trial of Neovascular Age-related Macular Degeneration, sponsored by Clearside Biomedical.

Completed
Registry status
15
Enrollment target
7
Study locations

NCT05131646 is a study of Neovascular Age-related Macular Degeneration that has completed, run by Clearside Biomedical. The registered enrollment target is 15 participants, below the 408-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (96% lower). The trial reports 7 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05131646, a study of Neovascular Age-related Macular Degeneration, has completed, sponsored by Clearside Biomedical.

COMPLETED
Registry status
15 participants
Enrollment target
7
Study locations

Study Summary

This is an open-label, non-interventional extension study of up to 12 weeks in duration in subjects completing Cohorts 2, 3, and 4 of the Parent study, CLS1002-101.

Conditions Studied

Neovascular Age-related Macular Degeneration

Interventions

  • DRUG CLS-AX

Study Locations (7)

California

  • Northern California Retina Vitreous Associates Medical Group, LLC - Mountain View
  • Retina Consultants Medical Group, Inc - Sacramento

Texas

  • Retina Consultants of Texas - Bellaire
  • Retina Consultants of Texas - The Woodlands

Arizona

  • Retinal Consultants of Arizona - Phoenix

Georgia

  • Southeast Retina Center - Augusta

Maryland

  • Cumberland Valley Retina Consultants - Hagerstown

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2021-10-08
Est. Completion 2023-01-05

Sponsor

Clearside Biomedical

14 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05131646

The ClinicalTrials.gov registry entry for NCT05131646 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 408-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (96% lower). The listed sponsor is Clearside Biomedical, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which CLS-AX is the first listed.

NCT05131646 reports 7 study locations spanning 5 distinct geographic areas - top geographies include California, Texas, Arizona.

Frequently Asked Questions

What is clinical trial NCT05131646 about?

NCT05131646 is a clinical study titled "Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study". This is an open-label, non-interventional extension study of up to 12 weeks in duration in subjects completing Cohorts 2, 3, and 4 of the Parent study, CLS1002-101.

What is the current status of trial NCT05131646?

This trial is currently completed. The enrollment target is 15 participants. The study started on 2021-10-08. Estimated completion is 2023-01-05.

What conditions does trial NCT05131646 study?

This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.

What interventions are being tested in trial NCT05131646?

The interventions under investigation include: CLS-AX (DRUG).

Who is sponsoring clinical trial NCT05131646?

This trial is sponsored by Clearside Biomedical, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05131646 being conducted?

This trial has 7 study locations across Arizona, California, Georgia, Maryland, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neovascular Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neovascular Age-related Macular Degeneration

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.